Psyence BioMed Completes $2.6 Million PsyLabs Investment as Ibogaine Program Advances

Key Points

• Psyence BioMed invested an additional $2.6 million in PsyLabs after two development milestones were met.
• PsyLabs completed a regulatory preparation package, while Psyence’s Texas subsidiary secured a U.S. manufacturing agreement with Benuvia.
• The investment increased Psyence’s ownership in PsyLabs from approximately 41.13% to 43.37%.
• The work supports a planned U.S. pharmaceutical-grade ibogaine program, but does not represent regulatory clearance to begin human trials.
• A definitive agreement making PsyLabs the exclusive U.S. ibogaine supplier to the Texas subsidiary remains pending.

Psyence Biomedical (NASDAQ: PBM) has completed an additional investment in PsyLabs, funding the next stage of preparation for its planned U.S. ibogaine development program.

The approximately $2.6 million payment was funded from existing cash and completed ahead of the December 31 deadline. It follows a previously announced commitment to invest up to $5 million in PsyLabs.

Regulatory Documentation and Manufacturing Agreement Unlock Funding

Two milestones triggered the additional investment.

First, PsyLabs completed a documentation package intended to support future regulatory discussions about pharmaceutical-grade ibogaine hydrochloride.

Second, Texas Ibogaine Research Corporation, or TIRC, signed a manufacturing services agreement with Benuvia. TIRC is Psyence’s wholly owned Texas subsidiary, while Benuvia operates a DEA-registered controlled-substance manufacturing facility in Round Rock, Texas.

The agreement is intended to support U.S. production of ibogaine’s active pharmaceutical ingredient under current Good Manufacturing Practice standards, subject to applicable requirements. It does not mean commercial production or clinical testing has been authorized.

PsyLabs and Texas Subsidiary Will Handle Different Parts of Development

The proposed structure gives PsyLabs responsibility for cultivation, extraction and supply, while TIRC handles U.S. manufacturing coordination, nonclinical work and regulatory development.

PsyLabs is expected to become TIRC’s exclusive ibogaine supplier for the United States. However, that arrangement still requires a definitive agreement, which the parties aim to complete by November 30, 2026.

Investment Raises Psyence’s Stake to Approximately 43.37%

Psyence acquired 1,014 additional PsyLabs shares for $2,599,896, increasing its ownership from approximately 41.13% to 43.37%.

Because PsyLabs is a related party and a significant Psyence shareholder, the transaction was reviewed and approved by Psyence’s independent special committee and audit committee.

Investor Takeaway: Development Infrastructure Advances, but Clinical Work Remains Ahead

For PBM investors, the update adds capital, regulatory preparation and a manufacturing relationship to the planned ibogaine program.

The next milestones include completing the supplier agreement and advancing the work needed before a U.S. human trial could be proposed. The announcement does not report clinical results, permission to begin a trial or an approved treatment.